U.S. Banks Stock News

NasdaqGS:ABNB
NasdaqGS:ABNBHospitality

The Bull Case For Airbnb (ABNB) Could Change Following Truist’s Profitability Upgrade – Learn Why

Earlier this week, Truist upgraded Airbnb to Hold from Sell after raising its 2026 adjusted EBITDA and earnings estimates, following Q4 results showing 16% year-over-year Gross Booking Value growth and Q1 2026 revenue guidance of 14%–16% growth. The upgrade underscores how Airbnb’s recent margin pressure was tied to spending on hotel partnerships and new services that Truist now expects to support improved profitability. Next, we’ll examine how Truist’s more optimistic view on Airbnb’s...
NYSE:CLF
NYSE:CLFMetals and Mining

Is Cleveland-Cliffs (CLF) Pricing Look Compelling After Steep Multi‑Year Share Price Declines?

Wondering whether Cleveland-Cliffs at a last close of US$8.11 offers value or a value trap? This breakdown will help you frame the price against what the business may be worth. The stock has recently shown mixed performance, with a 3.7% gain over the last 7 days but declines of 24.8% over 30 days, 40.4% year to date, and 4.8% over the past year. These moves sit against a longer track record that shows 55.8% and 58.2% declines over the past 3 and 5 years respectively. This can influence how...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA

Summit Therapeutics presented new Phase III data on ivonescimab at the 2026 European Lung Cancer Congress in EGFR mutated NSCLC. The data highlighted improved intracranial progression free survival, including in patients with brain metastases. The company has submitted a Biologics License Application to the FDA, with a PDUFA decision date set for November. Summit Therapeutics, trading as NasdaqGM:SMMT, is drawing attention after sharing these late stage results alongside a confirmed FDA...
NYSE:CWT
NYSE:CWTWater Utilities

A Look At California Water Service Group’s (CWT) Valuation After Mixed Return Signals

California Water Service Group (CWT) is back on watch after recent share price moves, with the stock showing mixed returns over the past year as investors reassess this regulated water utility. See our latest analysis for California Water Service Group. At a share price of $45.01, California Water Service Group has recently seen a 7 day share price return of 2.51% but the 1 year total shareholder return is a decline of 4.2%. This suggests that recent momentum contrasts with weaker longer term...
NYSE:SEI
NYSE:SEIEnergy Services

Is It Too Late To Reassess Solaris Energy Infrastructure (SEI) After Its 156% One-Year Surge?

If you are wondering whether Solaris Energy Infrastructure at US$57.83 is still attractively priced after its run, this section is designed to help you frame that question clearly. The stock has seen a 6.4% decline over the past week, a 4.7% gain over the last 30 days, a 15.1% gain year to date, and a 156.2% gain over the last year, which may signal shifting views on both its potential and its risks. Recent attention on the company has focused on its role in energy infrastructure and how...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

How Investors May Respond To Open Text (OTEX) Highlighting Enterprise Gaps In AI Risk And Governance

Earlier this month, OpenText released a global report with the Ponemon Institute on managing risks and optimizing the value of AI, generative AI, and agentic AI, highlighting that many enterprises have adopted these tools without fully developed security and governance frameworks. The study’s finding that only a small minority of enterprises fully embed AI into cybersecurity and risk assessment underlines a widening gap between AI deployment and risk management that could influence how...
NasdaqCM:SKYT
NasdaqCM:SKYTSemiconductor

A Look At SkyWater Technology (SKYT) Valuation After A 1 Year Return Above 200%

SkyWater Technology: recent returns and business mix SkyWater Technology (SKYT) has attracted attention after a sharp move in its share price over the past year, with a 1 year total return above 200% and a past 3 months return near 50%. The company, valued at about US$1.34b and recently closing at US$27.00, reports US$442.139m in revenue and net income of US$118.91m, with operations split between its Legacy SkyWater and SkyWater Texas segments. See our latest analysis for SkyWater...
NasdaqGS:DOX
NasdaqGS:DOXIT

A Look At Amdocs (DOX) Valuation After The Recent CEO Transition

Leadership change and why it matters for Amdocs (NasdaqGS:DOX) Amdocs (NasdaqGS:DOX) is in focus after Shuky Sheffer retired from both the management team and the Board, with Shimie Hortig taking over as President, Chief Executive Officer, and Board member. CEO transitions often prompt investors to reassess expectations around execution, capital allocation, and long term priorities, especially for a software and services business with a global communications and media customer base. See our...
NYSE:MKL
NYSE:MKLInsurance

Markel Taps New International CIO As Digital Execution Takes Center Stage

Markel Group (NYSE:MKL) has appointed Phil Jones as Chief Information Officer, International. Jones brings technology and operational experience across insurance, financial services, and government sectors. The role covers Markel International’s digital capabilities, operational resilience, and service delivery. For investors watching NYSE:MKL, this move highlights the growing importance of technology leadership for insurance and specialty risk businesses. As underwriting, claims, and...
NYSE:OGE
NYSE:OGEElectric Utilities

OGE Energy Issues Callable Notes As Valuation And Debt Come Into Focus

Oklahoma Gas and Electric Company, a subsidiary of OGE Energy (NYSE:OGE), announced a new fixed-income offering of callable senior and subordinated unsecured fixed rate notes. The notes are structured as unsecured obligations and include both senior and subordinated tranches, with fixed interest rates. The securities are callable, meaning the issuer may choose to redeem them before maturity, subject to the offering terms. OGE Energy, through Oklahoma Gas and Electric, operates as a...
NYSE:GRND
NYSE:GRNDInteractive Media and Services

Is It Time To Reconsider Grindr (GRND) After This Year’s Share Price Slide?

Some investors may be considering whether Grindr's current share price reflects its potential value, or whether the market is mispricing the stock at present. Over the past month, Grindr's share price has moved by 11.3%, while the 1 year return shows a 29.8% decline. This may draw the attention of investors who are weighing recent momentum against longer term performance. Recent coverage around Grindr has focused on its position as a listed interactive media and services platform, including...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

How Long-Term ATTRibute-CM Data on Acoramidis Could Shape BridgeBio Pharma’s (BBIO) Investment Story

BridgeBio Pharma has announced that long-term efficacy and safety results from the open-label extension of its Phase 3 ATTRibute-CM trial of acoramidis in ATTR-CM, including multiple analyses on survival, disease stabilization, and patient-reported outcomes, were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans on March 28–30, 2026. The new data, alongside real-world survey findings on treatment patterns and preferences in ATTR-CM, offer a deeper view...
NasdaqGS:GLBE
NasdaqGS:GLBEMultiline Retail

Is It Time To Reconsider Global E Online (GLBE) After Recent Share Price Weakness?

If you are wondering whether Global-E Online is starting to look attractive or still carries too much risk, its recent share price moves and current valuation metrics give you plenty to think about. The stock last closed at US$28.93, with returns of a 10.5% decline over 7 days, a 17.6% decline over 30 days, a 23.6% decline year to date and an 18.9% decline over 1 year. These moves may have shifted how the market is pricing its prospects and risks. These moves have come as Global-E Online...
NYSE:FUL
NYSE:FULChemicals

H.B. Fuller Secures Supply And Raises Prices While Refocusing On Balance Sheet

H.B. Fuller (NYSE:FUL) secured key raw materials after more than 40 force majeure notices linked to Middle East related supply disruptions. The company plans a minimum 10% global price increase effective April 1, 2026, to address inflation and raw material cost pressures. Management has paused acquisitions to focus on debt reduction and share buybacks, which signals a shift in capital allocation priorities. For investors watching NYSE:FUL, the share price sits at $59.17, with a 20.0% gain...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Should Biogen’s ALT-B4 Alzheimer’s Delivery Deal Reshape How BIIB Investors View Its Risk Profile?

In March 2026, Alteogen announced an exclusive license deal giving Biogen rights to develop subcutaneous formulations for two biologic products using ALT-B4 Hybrozyme technology, while new data from Eisai and Biogen showed strong long-term real-world treatment persistence for intravenous lecanemab in Alzheimer’s patients. Together, these developments highlight Biogen’s push to expand patient-friendly biologic delivery and deepen its presence in Alzheimer’s care through therapies patients are...
NYSE:DHR
NYSE:DHRLife Sciences

A Look At Danaher (DHR) Valuation After Recent Share Price Weakness

Why Danaher (DHR) Is Drawing Attention Now Danaher (DHR) is back on many watchlists after a period of weaker share performance, including a 13% decline over the past month and a 21% decline over the past 3 months. See our latest analysis for Danaher. At a share price of $181.52, Danaher’s recent 13% 1 month share price decline and 21% 3 month share price decline extend a tougher run, while the 1 year total shareholder return of 11% and 5 year total shareholder return of 7% indicate pressure...
NYSE:RVTY
NYSE:RVTYLife Sciences

Revvity Vote On Special Meetings And Stock Retention Meets Valuation Gap

Revvity (NYSE:RVTY) plans to hold its annual meeting on April 28, 2026. Shareholders will vote on a proposed bylaw change to let holders of 25% of shares call special meetings. Activist-backed proposals seek tighter executive stock retention requirements tied to equity compensation. Revvity, which operates in life sciences and diagnostics, sits in a sector where governance practices are closely watched, partly because R&D cycles and regulatory oversight can shape capital allocation...
NYSE:FAF
NYSE:FAFInsurance

How Investors Are Reacting To First American Financial (FAF) Surging Past Revenue Expectations

In its most recent quarter, First American Financial posted an exceptional performance with revenue rising 21.6% year on year, beating analyst forecasts by 15.2% and signaling strong recent business momentum. This combination of solid top-line growth and outperformance versus expectations highlights how the company’s operations have recently been executing ahead of what the market had modeled. We’ll now examine how this stronger-than-expected quarterly revenue performance might influence...
NYSE:DHT
NYSE:DHTOil and Gas

A Look At DHT Holdings (DHT) Valuation After Its New Shelf Registration Filing

Why DHT Holdings Filed a New Shelf Registration DHT Holdings (DHT) has filed an omnibus shelf registration covering common stock, preferred stock, warrants, and rights. This filing gives the tanker owner flexibility to raise capital or pursue corporate actions when market conditions appear suitable. See our latest analysis for DHT Holdings. The shelf registration comes after a strong run, with DHT’s 90-day share price return of 48.12% and year-to-date gain of 54.17%, while the 1-year total...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

Is It Time To Reassess eToro Group (ETOR) After This Year’s Share Price Slide?

If you are wondering whether eToro Group at around US$29.05 is a bargain or a value trap, this breakdown is designed to help you frame that question clearly. The share price closed at US$29.05, with a 1.3% decline over the past week, a 10.5% decline over the past month, and an 18.6% decline year to date, which may signal shifting views on both risk and potential. Recent coverage has focused on eToro Group as a publicly listed trading platform provider that gives investors access to a wide...
NasdaqGS:VRNS
NasdaqGS:VRNSSoftware

Varonis Systems (VRNS) Is Down 10.6% After Exiting On-Premise Business To Focus On AI SaaS

Earlier this month, Varonis Systems unexpectedly announced it will discontinue its on-premises solution, which contributed about 15% of revenue, after missing quarterly projections and shifting its focus more fully to its SaaS platform. At the same time, the company launched its new Varonis Atlas AI security platform and prepared high-profile presentations at RSA Conference 2026, underscoring a quicker pivot toward AI-driven, cloud-based data security. We’ll now examine how the accelerated...
NYSE:CBT
NYSE:CBTChemicals

Is Cabot (CBT) Pricing Look Attractive After Mixed Recent Share Performance?

If you are wondering whether Cabot's current share price reflects its true worth, this article breaks down the key valuation clues you can use to judge it for yourself. Cabot recently closed at US$74.11, with returns of 9.3% over the past week, a 2.3% decline over the past month, 10.5% year to date and a 7.7% decline over the past year. Taken together, these figures give mixed signals about how the market is currently pricing the stock. Recent coverage around Cabot has focused on its...
NasdaqGM:TTD
NasdaqGM:TTDMedia

Trade Desk Adds IPO Veteran Drew Vollero As Governance Pressures Mount

The Trade Desk (NasdaqGM:TTD) has appointed Drew Vollero to its board of directors. Vollero is a financial executive with IPO experience at Reddit and Snap. The appointment comes during a period of governance scrutiny and industry headwinds for The Trade Desk. The Trade Desk operates a digital advertising platform that helps brands and agencies buy ad inventory across channels such as connected TV, online video, and display. The broader ad tech space has been dealing with regulatory...
NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance?

Wondering if PTC Therapeutics at around US$66.13 is giving you a fair deal or asking too much for its future potential? This article breaks down what the current price might be implying. The stock has seen a mixed run recently, with a 1.3% gain over the last 7 days, a 2.4% decline over 30 days, a 13.8% decline year to date, a 21.9% return over 1 year, and 36.5% and 34.4% over 3 and 5 years respectively. Recent attention on PTC Therapeutics has centered on how investors are reassessing the...